MDS is a bone marrow failure disorder
2016 ASH Symposium – Presentations Available Below

2016 ASH Symposium - Presentations Available Below

These presentations can also be viewed as a CME/CE course for credits. To take this course and earn CME/CE credits – Click Here! 

Click the links below to view our presentations: 

Program Overview and Objectives
Stephen Nimer, MD

New WHO Classification of MDS
Robert Hasserjian, MD

Integrating Molecular Findings into the Diagnosis and Prognosis of MDS
Rafael Bejar, MD, PhD

Recent Insights into Therapy-related MDS
Richard Larson, MD

Emerging Immune-related Therapies in MDS/AML
Daniel T. Starczynowski

Novel Treatment of Biologic and Molecular Targets for MDS-related Anemias and Higher Risk Disease
Uwe Platzbecker, MD

Program Overview

New clinical classification of MDS, as well as the evaluation of the implications of molecular mutations, have generated valuable advances for aiding management of patients with this disease. These recent findings will be discussed during this program. The unique nature of treatment-related MDS as a specific subset of MDS will be also be reviewed. Given the understanding of immunologic abnormalities in MDS, therapeutic interventions using immune checkpoint inhibitors and T-cell based therapies will add to this discussion, as will a number of the novel treatments using biologic targeted approaches for anemias and higher risk patients.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe the new WHO classification of MDS
  • Differentiate molecular features which are useful for classifying MDS and aiding in diagnosis and therapeutic decision-making
  • Analyze differences in therapy-related MDS which need consideration for their treatment
  • Evaluate immune-related mechanisms and treatment approaches for patients with MDS
  • Identify novel biologic approaches for treating anemias associated with MDS

Featured Faculty

Rafael Bejar, MD, PhD

University of California, San Diego
Moores Cancer Center
La Jolla, California

Robert Hasserjian, MD

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Richard Larson, MD

University of Chicago
Chicago, Illinois

Uwe Platzbecker, MD

University Hospital Carl Gustav Carus
Dresden, Germany

Daniel T. Starczynowski, PhD

Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Review answers to commonly asked questions or get answers to your questions from an MDS expert